• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Bioengineering

FDA to study “three-parent embryos”

Bioengineer by Bioengineer
March 1, 2014
in Bioengineering
Reading Time: 1 min read
1
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

On February 25 and 26 the US Food and Drug Administration discussed the possibility of legalising three-parent embryos – or, in scientific lingo, “oocyte modification in assisted reproduction for the prevention of transmission of mitochondrial disease or treatment of infertility”.

FDA to study three-parent embryos

This procedure, which involves removing the nucleus from one human egg whose cytoplasm contains defective mitochondria and placing it in an enucleated egg with healthy DNA for subsequent fertilisation, is also being debated in the UK.

The measure is strongly opposed by the Center for Genetics and Society, which is promoting an open letter to the FDA. It claims that mitochondrial transfer is unsafe, is effectively experimentation on unconsenting human subjects, and would only help a handful of women. Most importantly, it constitutes germline modification, a form of eugenics. This is a bright line which no country has ever stepped across.

Story Source:

The above story is based on materials provided by bioedge, Michael Cook.

Share12Tweet8Share2ShareShareShare2

Related Posts

Why is the first Turkish bioengineering promotion website, Biyomuhendislik.com, so important?

February 4, 2023

Robo-fish

September 19, 2016

Mice born from ‘tricked’ eggs

September 17, 2016

UCLA researchers use stem cells to grow 3-D lung-in-a-dish

September 16, 2016
Please login to join discussion

POPULAR NEWS

  • blank

    Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    314 shares
    Share 126 Tweet 79
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    206 shares
    Share 82 Tweet 52
  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1301 shares
    Share 520 Tweet 325
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    138 shares
    Share 55 Tweet 35

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

CDCA7 Alleles Influence CG Methylation in Arabidopsis

Population Lifestyle Changes Boost Life Expectancy: Study

Hanyang University Researchers Unveil Innovative High-Resolution Mechanoluminescent Platform Technology

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.